Get the Stockscreener App
2.50
26.90%
0.53
After Hours:
2.58
0.08
+3.20%
Inflarx Nv stock is traded at $2.50, with a volume of 18.20M.
It is up +26.90% in the last 24 hours and up +165.00% over the past month.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.97
Open:
$2.55
24h Volume:
18.20M
Relative Volume:
18.34
Market Cap:
$180.73M
Revenue:
$208.60K
Net Income/Loss:
$-58.59M
P/E Ratio:
-2.7281
EPS:
-0.9164
Net Cash Flow:
$-47.11M
1W Performance:
+26.26%
1M Performance:
+165.00%
6M Performance:
+108.33%
1Y Performance:
+55.28%
1-Day Range:
$2.30
$2.86
1-Week Range:
$1.85
$2.86
52-Week Range:
$0.7113
$2.86
Inflarx Nv Stock (IFRX) Company Profile
Compare IFRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx Nv
|
2.50 | 142.42M | 208.60K | -58.59M | -47.11M | -0.9164 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inflarx Nv Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx Nv Stock (IFRX) Latest News
InflaRx Q1 2026 earnings preview - MSN
InflaRx stock surges on AAV drug development plan By Investing.com - Investing.com South Africa
InflaRx stock surges on AAV drug development plan - Investing.com
InflaRx prices $150M offering of ordinary shares - MSN
InflaRx prices $150M stock sale to fund pipeline and working capital - Stock Titan
InflaRx prices $150 million share offering at $2 per share - Investing.com
InflaRx Refocuses Izicopan on Vasculitis and Renal Diseases With Funding Runway to 2029 - TipRanks
InflaRx to develop izicopan for kidney disease treatment By Investing.com - Investing.com Australia
InflaRx (Nasdaq: IFRX) details izicopan kidney strategy and funding through 2029 - Stock Titan
InflaRx Files Q1 2026 Financials with SEC via Form 6-K - TipRanks
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares - ChartMill
Funded through 2029, InflaRx expands izicopan into kidney diseases - Stock Titan
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases - ChartMill
InflaRx (NASDAQ: IFRX) cuts Q1 loss but flags going concern risk - Stock Titan
Top 5 Hot Penny Stocks to Buy Now - Insider Monkey
MSN Money - MSN
InflaRx NV expected to post a loss of 14 cents a shareEarnings Preview - TradingView
InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study - TipRanks
Low reactive metabolite data support InflaRx (IFRX) oral C5aR1 drug - Stock Titan
InflaRx reports preclinical data on izicopan metabolite formation By Investing.com - Investing.com Australia
In liver lab tests, izicopan showed over 100-fold lower reactive conjugates - Stock Titan
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes - ChartMill
InflaRx regains Nasdaq compliance after shares trade above $1 - MSN
InfraRX Down Ahead of Next Quarterly Report - Baystreet.ca
IFRX - Finviz
InflaRx N.V. to Publish Q1 2026 Financial Results on May 7, 2026 - Quiver Quantitative
InflaRx to Report First Quarter 2026 Results on May 7, 2026 - ChartMill
InflaRx N.V. (NASDAQ:IFRX) Short Interest Update - MarketBeat
InflaRx (IFRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
InflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status - TipRanks
InflaRx (Nasdaq: IFRX) back in line with Nasdaq minimum bid price rule - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance By Investing.com - Investing.com Australia
Nasdaq closes InflaRx listing issue after stock holds above $1 - Stock Titan
InflaRx regains Nasdaq minimum bid price compliance - Investing.com
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - marketscreener.com
InflaRx NV (IFRX) price target decreased by 17.33% to 9.03 - MSN
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM - The Globe and Mail
InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer - MarketBeat
Oppenheimer Adjusts Price Target on InflaRx to $5 From $7, Maintains Outperform Rating - marketscreener.com
InflaRx receives Nasdaq notification - MSN
InflaRx (IFRX) investors back board authorities, article changes and LTIP 2026 - Stock Titan
Inflarx Nv Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):